Stock Details
REGN is Regeneron Pharmaceuticals, Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 629.42$. Average daily volumn in 3 months 697.12k. Market cap 65.79B



Stock symbol : REGN. Exchange : NasdaqGS. Currency : USD
Lastest price : 598.91$. Total volume : 60.15k. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Regeneron Pharmaceuticals, Inc. (REGN)
Last Price
598.91$
Change
2.35
Volume
60.15k

Previous Close596.56
Open594.79
Day Range592.61-601.19
Bid598.29 x 900
Ask598.62 x 800
Volume60.15k
Average Volume697.12k
Market Cap65.79B
Beta0.24
52 Week Range538.01-747.42
Trailing P/E8.44
Foward P/E13.83
Dividend (Yield %)N/A
Ex-Dividend DateN/A



Financial Details


According to Regeneron Pharmaceuticals, Inc.'s financial reports the company's revenue in 2021 were 16.07B an decrease( +100%) over the years 2020 revenue that were of 8.5B. In 2021 the company's total earnings were 8.08B while total earnings in 2020 were 3.51B( +166.67%).


Loading ...



Organization

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vei... n occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Market Cap:
65.79B
Revenue:
16.07B
Total Assets:
25.43B
Total Cash:
2.89B


News about "Regeneron Pharmaceuticals, Inc."

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Is A Bargain Stock You Should Consider.

Source from : marketingsentinel - 2 days ago

In the last trading session, 0.39 million Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) shares changed hands as the companyโ€™s beta touched 0.31. With the companyโ€™s per share price at $595.40 changed ...See details»


marion-mccourt-sells-1100-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn-stock-image

Marion Mccourt Sells 1,100 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock

Source from : Defense World - 12 hours ago

EVP Marion Mccourt sold 1,100 shares of the businessโ€™s stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $587.76, for a total transaction of $646,536.See details»


gateway-investment-advisers-llc-sells-153-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn-image

Gateway Investment Advisers LLC Sells 153 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Source from : ETF Daily News - 9 days ago

Gateway Investment Advisers LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN โ€“ Get Rating) by 13.9% in the first quarter, according to the company in its most recent ...See details»


wedbush-securities-inc-cuts-stock-position-in-regeneron-pharmaceuticals-inc-nasdaqregn-image

Wedbush Securities Inc. Cuts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Source from : Defense World - 2 days ago

Wedbush Securities Inc. decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN โ€“ Get Rating) by 4.1% during the first quarter, Holdings Channel.com reports. The fund owned ...See details»


ritholtz-wealth-management-grows-stake-in-regeneron-pharmaceuticals-inc-nasdaqregn-image

Ritholtz Wealth Management Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Source from : ETF Daily News - 8 days ago

Ritholtz Wealth Management boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN โ€“ Get Rating) by 10.4% in the 1st quarter, according to its most recent filing with the Securities and ...See details»


Regeneron Completes Purchase of Sanofi's Stake in Libtayoยฎ (cemiplimab)

Source from : Business Insider - 5 days ago

On May 31, 2022, Regeneron announced that it had successfully acquired Checkmate Pharmaceuticals, Inc. for a total equity value of approximately $250 million. As a result of the Checkmate ...See details»


Regeneron Pharmaceuticals Inc - Stock Dividends REGN

Source from : Morningstar%2c Inc. - 7 days ago

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.See details»


Regeneron Pharmaceuticals, Inc.'s (REGN) Management Presents at Goldman Sachs 43rd Annual Global Healthcare Conference (Transcript)

Source from : Seeking Alpha - 22 days ago

Really pleased to have the Regeneron team with us ... we did end up buying Checkmate Pharmaceuticals about a month ago, which for the three years that weโ€™ve been in existence, actually going ...See details»


Regeneron: FDA to Review Extended Eylea Regimen in Diabetic Retinopathy

Source from : Morningstar%2c Inc. - 7 days ago

Regeneron Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration will review its application seeking approval of an extended dosing of its blockbuster eye treatment Eylea.See details»


regenerons-eylea-sbla-for-16-week-dosing-regimen-in-diabetic-retinopathy-accepted-for-fda-review-image

Regeneron's EYLEA SBLA For 16-week Dosing Regimen In Diabetic Retinopathy Accepted For FDA Review

Source from : Nasdaq - 7 days ago

(REGN) said Wednesday that the U.S. Food and Drug Administration has accepted for review the EYLEA (aflibercept) Injection supplemental Biologics License Application or sBLA for an every 16-week 2 mg ...See details»


Cision PR Newswire

Source from : WJHL-TV - 7 days ago

2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the EYLEA ยฎ (aflibercept) Injection ...See details»


regeneron-regn-eylea-sbla-for-extended-regimen-accepted-image

Regeneron (REGN) Eylea sBLA for Extended Regimen Accepted

Source from : Yahoo News Singapore - 6 days ago

Regeneron Pharmaceuticals, Inc. REGN recently announced that its supplemental biologics License Application (sBLA) for ophthalmology drug Eylea has been accepted by the FDA for review. Eylea is a VEGF ...See details»


EYLEAยฎ (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review

Source from : Associated Press - 7 days ago

If approved, extended regimen would provide a longer treatment interval and additional dosing flexibility, alongside approved every 4- and 8-week dosing regimens. TARRYTOWN, N.Y., ...See details»


Intellia, Regeneron announce positive interim data from phase 1 study of CRISPR-based NTLA-2001 to treat transthyretin amyloidosis

Source from : Pharmabiz - 9 days ago

Intellia, Regeneron announce positive interim data from phase 1 study of CRISPR-based NTLA-2001 to treat transthyretin amyloidosis: Cambridge, Massachusetts Monday, June 27, 2022, ...See details»